Collegium Pharma Also Gets A "Pass"

Collegium Pharmaceutical (COLL) develops and markets medicines for pain management, focused largely on extended release formulations of addictive opioid-based drugs. Currently, the firm sells 3 drugs, each contributing about 30% of revenue. Xtampza ER is an extended release version of oxycodone. Nucynta ER is a similar formulation of tapentadol, another powerful opioid. Belbuca is a form of buprenorphine, a synthetic opioid that can also be highly addictive. I have a few concerns with investing in this one. First, after the recent purchase of Ironshore to add ADHD drug Journay ER, Collegium will have a substantial amount of debt and only about a 2x interest coverage ratio (that's risky). Second, there is board room drama, with former CEO Joe Ciaffoni forced out in May by founder Michael Heffernan. And finally, about 1/3rd of current sales are at risk in the next few years as Nucynta goes off-patent. Just too many issues with this one. I'm passing on adding it to the Watch List.

Watch List

APPF 1.76%
CMG 41.39%
VEEV 15.19%
INTU 18.43%
WDAY -7.41%
PSTG -1.35%
RDDT 21.21%
NTNX 25.72%
CRWD 93.19%
SE 28.99%
SNOW 13.54%

Buy List

PINS -36.17%
SEMR -34.19%
TSM -41.43%
ZETA -25.56%
GOOG -49.87%
NYAX -28.83%
MSFT -28.75%
ODD -28.48%
FLYW -41.42%
HRMY -59.78%
YOU -38.88%
ABNB -30.73%
ADBE -42.67%

Hold List

ASML -23.38%
VTEX -14.40%
ASR -24.34%
CELH 43.72%
TOST 19.13%
CPNG -11.62%
HIMS -18.63%
PAYC -18.53%
MNDY 18.86%
GLBE -22.26%
ZS 34.88%
V -6.51%
ADSK 0.54%
NOW 13.21%
MELI -23.90%
FTNT 0.63%
TEAM 0.80%